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Vancomycin is U.S. Food and Drug Administration (FDA) approved for treatment of serious infections caused by methicillin-
resistant Staphylococcus aureus (MRSA) or in individuals who have failed, cannot tolerate, or are allergic to other antibiotics.
Very few cases of vancomycin-associated leukocytoclastic vasculitis have been published. We report on a patient who developed
pruritus and palpable purpura in both lower extremities after receiving six days of intravenous vancomycin. Skin biopsy revealed
leukocytoclastic vasculitis.
1.CaseReportand Discussion
A 52-year-old white female with history of intravenous
heroin abuse presented with a 10-day history of productive
cough associated with right-sided pleuritic chest pain. She
had a past medical history of one generalized tonic-clonic
seizure in 2007 for which she was on phenytoin without
evidence of further episodes; phenytoin was stopped by
the patient three months prior to this admission. Other
medications administered during her hospital stay include
tizanidine, albuterol/ipratropium inhaler, docusate, clonaze-
pam, lidocaine patch, and heparin sulfate subcutaneous
injection. Onphysical examination she was febrile with max-
imum temperature of 100.6◦F (38.1◦C). She had decreased
breath sounds over her right lower lung and CXR, and
CT chest demonstrated right-sided pleural eﬀusion. Blood
cultures and cultures from right thoracentesis specimens
revealed MRSA bacteremia and empyema, respectively, for
which the patient was started on vancomycin 1gm IV q
12hours. This dose provided a vancomycin steady state
serum trough concentration of 13.3mcg/mL. The dose was
escalated to 1250mg q 12 hours resulting in a steady
state serum trough concentration of 13.6mcg/mL, and then
to 1500mg q12 hours, yielding a 9-hour concentration
of 21.3mcg/mL following the 4th 1500mg dose, which
was deemed therapeutic. Serum creatinine values ranged
from 0.80 to 1.02 throughout the course of vancomycin
therapy. The patient improved clinically, and blood cultures
became sterile after three days of vancomycin. On day 6 of
vancomycin the patient developed pruritus and a palpable
nonblanching erythematous rash on her legs and buttocks
(Figure 1). On the following day, the appearance of the
rash was worse. Laboratory evaluationincludedcomplement
levels,HIVantibodytest,HCVPCR,antinuclearcytoplasmic
antibody, antinuclear antibodies, serum cryoglobulin, and
urinalysis, which were all negative/within normal range.
Transesophageal echocardiography did not reveal any valvu-
lar vegetations. The dermatologist was consulted and per-
formed a skin biopsy which showed ﬁndings consistent
with leukocytoclastic vasculitis (Figure 2). Subsequently, we
replaced vancomycin with linezolid. The other medications
that the patient was on were thought to be a much less likely
cause of the rash and were maintained. In the following
days, without adding steroids or other treatments, the rash
improved spontaneously. Complete recovery was noted 18
days thereafter.
Leukocytoclastic vasculitis (LV) is a small vessel inﬂam-
matory disease that is limited to the skin, predominantly of
thelowerextremities,andusuallysparespalmsandsoles.The
most commonskin manifestation ispalpablepurpura. Other2 Case Reports in Infectious Diseases
Figure 1: On day 6 after starting vancomycin, the patient develops
a pruritic, nonblanching erythematous rash on both legs, buttocks
and lower back area.
skin manifestations include maculopapular rash, bullae, pa-
pules, nodules, ulcers, and livedo reticularis. There is no
speciﬁc laboratory test for LV. The diagnosis is based on
the clinical picture and histopathologic features of the skin
biopsy. It is thought that the pathogenesis involves circulat-
ing immune complexes being deposited into vessel walls and
activating the complement pathway. Causes of LV include
drugs, infection, connective tissue disease, and malignancy.
Drugs may act as haptens and activate the immune response.
An estimated 10–20% of all cutaneous vasculitis cases
are attributed to drug administration including β-lactams,
diuretics, NSAIDs, methotrexate, azathioprine, etanercept,
cyclosporine, allopurinol, sulfasalazine, gold salts, antithy-
roid agents, anticonvulsants, and antiarrhythmics [1]. By
far, antibiotics have been the most common drugs reported
to cause cutaneous vasculitis, especially β-lactams [2]. Van-
comycin is well recognized as the cause of diﬀerent types of
hypersensitivityreactions, includingredmansyndrome,IgE-
mediated anaphylaxis, and immune-mediated skin reactions
such as vancomycin-related linear IgA bullous dermatosis
[3–5].
Vancomycin-related leukocytoclastic vasculitis has rarely
been reported [6–9]. From previous published case reports,
vancomycin-associated small vessel vasculitis can develop
after only a single dose of vancomycin [6]. The onset of vas-
culitis can occur as late as one month after administration
[7, 8]. In one report LV developed after completing a 21-
day treatment course and cessation of vancomycin for six
days [9]. The time to recovery varies between days and
weeks. Most cases of LV are self-limited and resolve without
sequelae. The preferred treatment is withdrawal of the
suspected oﬀending agent(s) [7]. Oral corticosteroids have
been used for LV; however, their eﬃcacy is not impressive.
Figure 2: High power view (400x) shows perivascular neutrophilic
inﬁltrate with ﬁbrinoid necrosis of vessel wall, abundant nuclear
dust and red blood cell extravasation.
Most of the patients had no change in disease course and
one-third showed transient improvement, but relapse was
observed when corticosteroids were tapered [10]. Colchicine
and dapsone may be used in patients with limited palpable
purpura without ulceration.
We were not able to identify alternative causes for the
vasculitis in our case, and the time course was consistent
with vancomycin-associated LV. In the presence of newly
developed palpable purpura, vancomycin has to be consid-
ered as a potential cause of leukocytoclastic vasculitis, and
discontinuing the oﬀending medication is the most eﬀective
approach.
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